NCT07159399Enrolling by invitation
A Pharmacist-Led Education Program to Improve Adherence to Direct Oral Anticoagulants in Patients With Atrial Fibrillation
Impact of a Pharmacist-Led Education Program on Medication Adherence and Treatment Effectiveness of Direct Oral Anticoagulants in Patients With Atrial Fibrillation: A Randomized Controlled Trial
Source: ClinicalTrials.gov · Last updated 8 Sept 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
Atrial fibrillation (irregular heartbeat) increases the risk of stroke, and patients are commonly treated with direct oral anticoagulants (DOACs). However, when patients do not take these medications regularly, the drugs may not work effectively, increasing health risks. In this study, called PharmAD-AF, specially trained pharmacists will meet with patients who have atrial fibrillation and are prescribed DOACs. They will offer personalized education and support to help patients take their medications as directed. Researchers will compare groups of patients who receive this pharmacist-led education versus those who receive usual care. The main goals are to assess whether pharmacist support improves how consistently patients take their DOACs and how well the treatment prevents strokes while avoiding the side effects of DOAC therapy. If successful, the study will demonstrate how pharmacist-led education can help patients stick to their treatment plan and reduce serious health risks, offering a practical way to improve heart-related care.
- Status (registry)
- Enrolling by invitation
- Study type
- Interventional
- Enrollment
- 400 (estimated)
- First submitted
- 25 Aug 2025
- Start date
- 5 Mar 2025
- Primary completion date
- 31 Dec 2027
- Lead sponsor
- National Taiwan University
- Diseases
- Atrial fibrillation
- NCT number
- NCT07159399
What you commit to
- Study type: Interventional
- Planned participants: 400
- From 5 Mar 2025 to the primary completion date, 31 Dec 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- have been on DOAC therapy for more than 6 months
Other illness
- cannot understand DOAC-related education due to low literacy, language barriers, or cognitive impairment
Other
- using DOACs in off-label regimens
- are pregnant or breastfeeding
Who the study is looking for
- 18 years of age or older
- have a confirmed diagnosis of AF
- are expected to begin DOAC therapy for at least 3 months for stroke prevention
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| National Taiwan University Hospital Coordinator of this site? Confirm its status | Taipei | Taiwan | Unknown status |
Related publications
- Pharmacist-Led Intervention to Enhance Direct Oral Anticoagulant Adherence and Treatment Outcomes in Atrial Fibrillation: A Pragmatic Clinical Trial.Patient Prefer Adherence · 2026 · PMID 41858640
This page is information, not medical advice. Discuss any trial with your doctor.